C7R-GD2.CART cells / Baylor College of Medicine - LARVOL DELTA

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine

Biomarker • New P1 trial • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

C7R-GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors (GAIL-B) (clinicaltrials.gov) - P1 | N=37 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2039 ➔ Feb 2041 | Trial primary completion date: Feb 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Embryonal Tumor • Glioma • Malignant Glioma • Oncology • Solid Tumor

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Active, not recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2039 ➔ May 2038

CAR T-Cell Therapy • Trial completion date • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2038 ➔ Dec 2039 | Trial primary completion date: Jun 2023 ➔ Jun 2024

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Neuroendocrine Tumor • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2038 ➔ Feb 2039 | Trial primary completion date: Feb 2023 ➔ Feb 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Embryonal Tumor • Glioma • Oncology • Solid Tumor

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2037 ➔ Dec 2038 | Trial primary completion date: Jun 2022 ➔ Jun 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Breast Cancer • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma